1Lebovitz HE, Dole JE, Patwardhnan R, et al. Rosiglitazone monotherapy is effective in patie nts with type 2 diabetes. J Cin Endocrinol Metab 2001 ,86:280- 288.
2Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent anti - inflammatory effect of rosiglitazone. J Clin Endocrinol Meatab 2004,89(6) :2728 - 35.
3Steward M, Jones NP, Krieder M, et al. Combiation effects If rosiglitazone and atorvas tatin on the dyslipidemia association with type 2 diabetes. Diabetologia 2001,44 (Suppl 1 ) : Abstract 854.
4Freed M, Fuell D, Menci L, et al. Effects of combination therapy with rosiglitaxzone and glibenclamide on PAI- 1 and tPA in patients with type 2 diabetes. Doabe tologia 2000,43(Suppl 1) :A1024.
5Boden G, Ruiz J, Kim CJ, et al. Effects of prolonged glucose infusion on insulin secretion, clearance, and action in normal subjects. Am J Physiol, 1996,270(2 Pt 1):E251-258.
6Kawai K, Yokota C, Ohashi S, et al. Evidence that glucagon stimulates insulin secretion through its own receptor in rats. Diabetologia, 1995, 38:274-276.
7Straub SG, James RF, Dunne MJ, et al. Glucose activates both K(ATP) channel-dependent and K(ATP) channel-independent signaling pathways in human islets. Diabetes, 1998,47:758-763.
8Gjessing HJ, Reinhold B, Pedersen O. The effect of chronic hyperglycaemia on the islet B-cell responsiveness in newly diagnosed type 2 diabetes. Diabet Med, 1992,9:601-604.
9Ko GT, Chan JC, Woo J, et al. The reproducibility and usefulness of the oral glucose tolerance test in screening for diabetes and other cardiovascular risk factors. Ann Clin Biochem, 1998,35:62-67.
10Wolffrenbuttel BHR,Gomist R,Squatrito S,et al.Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycaemic control in type 2 diabetic patients.Diabetic Med,2000,17:40-47.
